4507 Stock Overview
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Shionogi & Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,264.50 |
| 52 Week High | JP¥2,712.33 |
| 52 Week Low | JP¥1,944.67 |
| Beta | 0.28 |
| 1 Month Change | 1.46% |
| 3 Month Change | 8.12% |
| 1 Year Change | -4.95% |
| 3 Year Change | -10.76% |
| 5 Year Change | 16.23% |
| Change since IPO | 620.41% |
Recent News & Updates
We Think Shionogi's (TSE:4507) Healthy Earnings Might Be Conservative
Feb 07
Shionogi & Co., Ltd. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 04There's Reason For Concern Over Shionogi & Co., Ltd.'s (TSE:4507) Price
Nov 26Recent updates
We Think Shionogi's (TSE:4507) Healthy Earnings Might Be Conservative
Feb 07Shionogi & Co., Ltd. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 04There's Reason For Concern Over Shionogi & Co., Ltd.'s (TSE:4507) Price
Nov 26Shionogi & Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 30Shionogi's (TSE:4507) Dividend Will Be ¥85.00
Sep 11Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00
Aug 28Shionogi's (TSE:4507) Dividend Will Be ¥85.00
Aug 09Shionogi & Co., Ltd. Just Missed EPS By 20%: Here's What Analysts Think Will Happen Next
Jul 31Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00
Jul 26Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00
Jul 11Shionogi's (TSE:4507) Soft Earnings Don't Show The Whole Picture
Jun 28Is Shionogi & Co., Ltd. (TSE:4507) Trading At A 28% Discount?
May 07Shionogi & Co., Ltd.'s (TSE:4507) Shares May Have Run Too Fast Too Soon
Mar 22Shionogi (TSE:4507) Will Pay A Dividend Of ¥75.00
Mar 01Shareholder Returns
| 4507 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 4.3% | -3.0% | -1.3% |
| 1Y | -4.9% | -3.5% | 1.8% |
Return vs Industry: 4507 underperformed the JP Pharmaceuticals industry which returned -3.5% over the past year.
Return vs Market: 4507 underperformed the JP Market which returned 1.8% over the past year.
Price Volatility
| 4507 volatility | |
|---|---|
| 4507 Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.4% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4507 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4507's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1878 | 4,959 | Isao Teshirogi | www.shionogi.com |
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
Shionogi & Co., Ltd. Fundamentals Summary
| 4507 fundamental statistics | |
|---|---|
| Market cap | JP¥1.87t |
| Earnings (TTM) | JP¥168.61b |
| Revenue (TTM) | JP¥456.87b |
11.4x
P/E Ratio4.2x
P/S RatioIs 4507 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4507 income statement (TTM) | |
|---|---|
| Revenue | JP¥456.87b |
| Cost of Revenue | JP¥61.24b |
| Gross Profit | JP¥395.63b |
| Other Expenses | JP¥227.02b |
| Earnings | JP¥168.61b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 12, 2025
| Earnings per share (EPS) | 198.21 |
| Gross Margin | 86.60% |
| Net Profit Margin | 36.91% |
| Debt/Equity Ratio | 0% |
How did 4507 perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield57%
Payout RatioDoes 4507 pay a reliable dividends?
See 4507 dividend history and benchmarks| Shionogi dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Jun 23 2025 |
| Days until Ex dividend | 35 days |
| Days until Dividend pay date | 122 days |
Does 4507 pay a reliable dividends?
See 4507 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 10:15 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shionogi & Co., Ltd. is covered by 26 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Aaron Ho | CFRA Equity Research |